Ampio Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>AP</div>
AMPE -- USA Stock  

USD 1.43  0.07  5.15%

As many of us are excited about healthcare space, it is fair to digest Ampio Pharmaceuticals within current market trends. We are going to address the reasons why we are still confident in anticipation of a recovery. The returns on the market and returns on Ampio Pharmaceuticals appear slightly-related for the last few months. The appearance of sound basic indicators of the firm indicates a shorter-term price swing for shareholders of Ampio. The next fiscal quarter end is expected on the 31st of December 2020. The stock experiences an active upward rally.
Published over three weeks ago
View all stories for Ampio Pharmaceuticals | View All Stories
Planning to continue with Ampio Pharmaceuticals (NYSEMKT:AMPE) in January?
This firm's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Ampio Pharmaceuticals market sentiment investors' perception of the future value of Ampio. Let us look at a few aspects of Ampio technical analysis. The company recorded a loss per share of 0.11. Ampio Pharmaceuticals had not issued any dividends in recent years. The entity had 1:3 split on the 1st of August 2008.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Ampio Pharmaceuticals. In general, we focus on analyzing Ampio Pharmaceuticals stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ampio Pharmaceuticals's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Ampio Pharmaceuticals's intrinsic value. In addition to deriving basic predictive indicators for Ampio Pharmaceuticals, we also check how macroeconomic factors affect Ampio Pharmaceuticals price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Ampio Pharmaceuticals' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Ampio Pharmaceuticals in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Ampio Pharmaceuticals. Your research has to be compared to or analyzed against Ampio Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Ampio Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Ampio Pharmaceuticals.

Watch out for price decline

Please consider monitoring Ampio Pharmaceuticals on a daily basis if you are holding a position in it. Ampio Pharmaceuticals is trading at a penny-stock level, and the possibility of delisting is much higher compared to other equities. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion. Most exchanges require public instruments, such as Ampio Pharmaceuticals stock to be traded above the $1 level to remain listed. If Ampio Pharmaceuticals stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.

How does Ampio Stands against Peers?

Analyzing Ampio Pharmaceuticals competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Ampio Pharmaceuticals across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Ampio Pharmaceuticals Competition Details

How Ampio utilizes its cash?

To perform a cash flow analysis of Ampio Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Ampio Pharmaceuticals is receiving and how much cash it distributes out in a given period. The Ampio Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Ampio Pharmaceuticals Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (13.84 Million)

Closer look at Ampio Pharmaceuticals Variance

Ampio Pharmaceuticals has current Variance of 61.46. Variance is another measure of security risk that shows the amount of dispersion of equity returns around their mean value. Variance is calculated as the average squared deviations from the mean. Evaluating a set of investment alternatives one can use variance to help determine the volatility when purchasing a specific security. Similar to Standard Deviation, the variance is a measure of how far a set of numbers is spread out around its mean.

Variance is also a measure of stock volatility and can help determine the risk an investor might take on when purchasing a specific security. A relatively big variance indicates that the daily prices or returns are far from the mean and a small variance indicates that they are located around the mean.

Variance 
 = 
SUM(RET DEV)2 
 = 
61.46
SUM = Summation notation
RET DEV = Actual returns deviation over selected period
N = Number of points for the period
Let's now compare Ampio Pharmaceuticals Variance to its closest peers:
AMPE
NK
DYAI
DVAX
EARS
AMPE61.459577919934695
NK45.44
DYAI8.38
DVAX24.42
EARS2,136.35

Are Ampio Pharmaceuticals technical ratios showing a reversion?

The total risk alpha is down to 0.89 as of today. Ampio Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize Ampio Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about Ampio Pharmaceuticals volatility.

Our Final Perspective on Ampio Pharmaceuticals

Although some companies under the biotechnology industry are still a bit expensive, Ampio Pharmaceuticals may offer a potential longer-term growth to shareholders. With a relatively neutral outlook on the latest economy, it is better to hold off any trading of Ampio as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Ampio Pharmaceuticals.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Ampio Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com